Partnership enabling Alzheimer's disease drug development
Recombinant Technologies now aims to complete Investigational New Drug (IND)-enabling, pre-clinical studies to progress the development of these innovative AmyTrap drug candidates.
"We are happy to partner with Health Connexions" and leverage their expertise, making Recombinant Technologies' promising, potential cure for Alzheimer's disease well-known, and ready AmyTrap for further investment and development,"said Dr.Sundaram. .
Health Connexions is working with Recombinant Technologies to coordinate the receipt of expressions of interest from biopharmaceutical companies, investment banks, funding bodies, and others interested in providing the capital to fund a possible cure for Alzheimer's disease. With the number of people with Alzheimer's disease expected to quadruple from over 26 million in 2006 to 106 million worldwide in 2050, for investors, this market holds an unprecedented potential return on investment.
Health Connexions:
The Health Connexions vision is to transform science into commercial success. Health Connexions helps clients in the life sciences and health care sectors by leveraging its extensive network and unique collaborative model in consulting, market research, technology evaluations and marketing communications services. Health Connexions also provides strategic advisory services for capital raising to fund new innovations, new opportunities, and the growth of established organizations. Visit www.healthconnexions.com.
Recombinant Technologies:
Recombinant Technologies is a specialized biotechnology company with world-leading expertise in retro inverse peptides and Alzheimer's disease. It was founded in 1999 by Dr. Pazhani Sundaram to market novel biological reagents from Yale University research; Dr. Sundaram is the co-inventor of AmyTrap and already has one drug in the market, based on his research.Recombinant Technologies is based in Cheshire, CT.
Contacts
Dawn Van Dam, President & CEO
Health Connexions
416-402-8274
dawn@healthconnexions.com